Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience

Luca Arcaini, Daniele Laszlo, Silvia Rizzi, Monica Balzarotti, Francesca Antoniazzi, Vittorio Ruggero Zilioli, Elena Guggiari, Lucia Farina, Elisabetta Todisco, Maurizio Bonfichi, Sara Miqueleiz Alamos, Giuseppe Rossi, Giovanni Martinelli, Enrica Morra

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Plerixafor has been previously reported to improve PBSC collection in pts undergoing PBSC mobilization. Aim of the study was to assess the efficacy of plerixafor and G-CSF in pts with lymphoma who failed previous attempts of PBSC mobilization with conventional schemes of chemotherapy+G-CSF. 35 heavily pre-treated lymphoma pts (29 NHL, 6 HL) classified as " poor mobilizers" were enrolled in a program of compassionate use of plerixafor in 7 Italian centres of REL (Rete Ematologica Lombarda). Median number of previous lines of therapy was 3 and median number of previous attempts of mobilizations was 2. The median number of circulating CD34+ cells/μL following plerixafor was 11/μL. It was ≥10/μL in 17 pts and ≥20/μL in 10 pts; 13 were able to collect ≥2×10 6 CD34+ cells/kg with a median of 1 apheresis procedure; 4 pts collected ≥4×10 6 CD34+ cells/kg. A total of 6 pts had proceeded to transplant at the time of analysis. The median dose of PBSCs infused was 4×10 6/kg and hematopoietic recovery was regular. In conclusion, plerixafor combined with G-CSF allows a collection of adequate number of PBSC in approximately 40% of cases of poor mobilizer, heavily pre-treated pts with lymphoma, who need consolidation with ASCT.

Original languageEnglish
Pages (from-to)712-714
Number of pages3
JournalLeukemia Research
Volume35
Issue number6
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Granulocyte Colony-Stimulating Factor
Lymphoma
Drug Therapy
Compassionate Use Trials
Blood Component Removal
JM 3100
Transplants

Keywords

  • Lymphoma
  • PBSC mobilization
  • Plerixafor
  • Poor mobilizers

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy : A REL (Rete Ematologica Lombarda) experience. / Arcaini, Luca; Laszlo, Daniele; Rizzi, Silvia; Balzarotti, Monica; Antoniazzi, Francesca; Zilioli, Vittorio Ruggero; Guggiari, Elena; Farina, Lucia; Todisco, Elisabetta; Bonfichi, Maurizio; Alamos, Sara Miqueleiz; Rossi, Giuseppe; Martinelli, Giovanni; Morra, Enrica.

In: Leukemia Research, Vol. 35, No. 6, 06.2011, p. 712-714.

Research output: Contribution to journalArticle

Arcaini, Luca ; Laszlo, Daniele ; Rizzi, Silvia ; Balzarotti, Monica ; Antoniazzi, Francesca ; Zilioli, Vittorio Ruggero ; Guggiari, Elena ; Farina, Lucia ; Todisco, Elisabetta ; Bonfichi, Maurizio ; Alamos, Sara Miqueleiz ; Rossi, Giuseppe ; Martinelli, Giovanni ; Morra, Enrica. / Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy : A REL (Rete Ematologica Lombarda) experience. In: Leukemia Research. 2011 ; Vol. 35, No. 6. pp. 712-714.
@article{05457fb1c9b145a0bace7aa58dcd2037,
title = "Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience",
abstract = "Plerixafor has been previously reported to improve PBSC collection in pts undergoing PBSC mobilization. Aim of the study was to assess the efficacy of plerixafor and G-CSF in pts with lymphoma who failed previous attempts of PBSC mobilization with conventional schemes of chemotherapy+G-CSF. 35 heavily pre-treated lymphoma pts (29 NHL, 6 HL) classified as {"} poor mobilizers{"} were enrolled in a program of compassionate use of plerixafor in 7 Italian centres of REL (Rete Ematologica Lombarda). Median number of previous lines of therapy was 3 and median number of previous attempts of mobilizations was 2. The median number of circulating CD34+ cells/μL following plerixafor was 11/μL. It was ≥10/μL in 17 pts and ≥20/μL in 10 pts; 13 were able to collect ≥2×10 6 CD34+ cells/kg with a median of 1 apheresis procedure; 4 pts collected ≥4×10 6 CD34+ cells/kg. A total of 6 pts had proceeded to transplant at the time of analysis. The median dose of PBSCs infused was 4×10 6/kg and hematopoietic recovery was regular. In conclusion, plerixafor combined with G-CSF allows a collection of adequate number of PBSC in approximately 40{\%} of cases of poor mobilizer, heavily pre-treated pts with lymphoma, who need consolidation with ASCT.",
keywords = "Lymphoma, PBSC mobilization, Plerixafor, Poor mobilizers",
author = "Luca Arcaini and Daniele Laszlo and Silvia Rizzi and Monica Balzarotti and Francesca Antoniazzi and Zilioli, {Vittorio Ruggero} and Elena Guggiari and Lucia Farina and Elisabetta Todisco and Maurizio Bonfichi and Alamos, {Sara Miqueleiz} and Giuseppe Rossi and Giovanni Martinelli and Enrica Morra",
year = "2011",
month = "6",
doi = "10.1016/j.leukres.2010.12.036",
language = "English",
volume = "35",
pages = "712--714",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",
number = "6",

}

TY - JOUR

T1 - Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy

T2 - A REL (Rete Ematologica Lombarda) experience

AU - Arcaini, Luca

AU - Laszlo, Daniele

AU - Rizzi, Silvia

AU - Balzarotti, Monica

AU - Antoniazzi, Francesca

AU - Zilioli, Vittorio Ruggero

AU - Guggiari, Elena

AU - Farina, Lucia

AU - Todisco, Elisabetta

AU - Bonfichi, Maurizio

AU - Alamos, Sara Miqueleiz

AU - Rossi, Giuseppe

AU - Martinelli, Giovanni

AU - Morra, Enrica

PY - 2011/6

Y1 - 2011/6

N2 - Plerixafor has been previously reported to improve PBSC collection in pts undergoing PBSC mobilization. Aim of the study was to assess the efficacy of plerixafor and G-CSF in pts with lymphoma who failed previous attempts of PBSC mobilization with conventional schemes of chemotherapy+G-CSF. 35 heavily pre-treated lymphoma pts (29 NHL, 6 HL) classified as " poor mobilizers" were enrolled in a program of compassionate use of plerixafor in 7 Italian centres of REL (Rete Ematologica Lombarda). Median number of previous lines of therapy was 3 and median number of previous attempts of mobilizations was 2. The median number of circulating CD34+ cells/μL following plerixafor was 11/μL. It was ≥10/μL in 17 pts and ≥20/μL in 10 pts; 13 were able to collect ≥2×10 6 CD34+ cells/kg with a median of 1 apheresis procedure; 4 pts collected ≥4×10 6 CD34+ cells/kg. A total of 6 pts had proceeded to transplant at the time of analysis. The median dose of PBSCs infused was 4×10 6/kg and hematopoietic recovery was regular. In conclusion, plerixafor combined with G-CSF allows a collection of adequate number of PBSC in approximately 40% of cases of poor mobilizer, heavily pre-treated pts with lymphoma, who need consolidation with ASCT.

AB - Plerixafor has been previously reported to improve PBSC collection in pts undergoing PBSC mobilization. Aim of the study was to assess the efficacy of plerixafor and G-CSF in pts with lymphoma who failed previous attempts of PBSC mobilization with conventional schemes of chemotherapy+G-CSF. 35 heavily pre-treated lymphoma pts (29 NHL, 6 HL) classified as " poor mobilizers" were enrolled in a program of compassionate use of plerixafor in 7 Italian centres of REL (Rete Ematologica Lombarda). Median number of previous lines of therapy was 3 and median number of previous attempts of mobilizations was 2. The median number of circulating CD34+ cells/μL following plerixafor was 11/μL. It was ≥10/μL in 17 pts and ≥20/μL in 10 pts; 13 were able to collect ≥2×10 6 CD34+ cells/kg with a median of 1 apheresis procedure; 4 pts collected ≥4×10 6 CD34+ cells/kg. A total of 6 pts had proceeded to transplant at the time of analysis. The median dose of PBSCs infused was 4×10 6/kg and hematopoietic recovery was regular. In conclusion, plerixafor combined with G-CSF allows a collection of adequate number of PBSC in approximately 40% of cases of poor mobilizer, heavily pre-treated pts with lymphoma, who need consolidation with ASCT.

KW - Lymphoma

KW - PBSC mobilization

KW - Plerixafor

KW - Poor mobilizers

UR - http://www.scopus.com/inward/record.url?scp=79955584638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955584638&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2010.12.036

DO - 10.1016/j.leukres.2010.12.036

M3 - Article

C2 - 21276613

AN - SCOPUS:79955584638

VL - 35

SP - 712

EP - 714

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 6

ER -